What Is Concurrent Chemoradiation Therapy (CCRT)?

Concurrent chemoradiation therapy, commonly abbreviated CCRT, is a cancer treatment strategy in which chemotherapy drugs and radiation therapy are delivered during the same time period rather than one after the other. The approach exploits a biological principle: certain chemotherapy agents make tumor cells more vulnerable to radiation damage, and radiation in turn can make tumors more responsive to drugs. This dual attack has become the standard of care for several locally advanced cancers, including head and neck, cervical, lung, and brain tumors, and the evidence behind it stretches back decades. But the combination also intensifies side effects, raises practical questions about who can tolerate it, and has recently become the launching pad for a new generation of immunotherapy strategies.

How Giving Both Treatments at Once Changes the Biology

The idea behind CCRT is not simply “more treatment is better.” Specific chemotherapy drugs interact with radiation at the molecular and cellular level in ways that amplify tumor-killing beyond what either therapy achieves alone. These interactions happen on several fronts. At the DNA level, drugs like cisplatin form chemical bonds with DNA strands that interfere with the cell’s ability to repair the breaks caused by radiation. One study found that cisplatin binding to DNA roughly doubled the amount of certain base damage produced by radiation exposure, making each radiation dose more destructive to the tumor than it would otherwise be.1The Journal of Physical Chemistry C. Chemoradiation Cancer Therapy: Molecular Mechanisms of Cisplatin Radiosensitization

At the cellular level, some drugs push cancer cells into phases of their growth cycle where they are most susceptible to radiation damage. Gemcitabine, for instance, arrests cells in the early phase of DNA replication, a stage when radiation is particularly lethal.2Scientific Reports. Cell-cycle-controlled radiation therapy was effective for treating a murine malignant melanoma cell line in vitro and in vivo The fluoropyrimidines, including 5-fluorouracil, work by a related mechanism: they cause cells to progress inappropriately into DNA synthesis, and those cells then fail to correctly repair radiation-induced damage.3PubMed. The mechanism of action of radiosensitization of conventional chemotherapeutic agents

Beyond what happens inside individual cells, the combination also acts at the tissue level. Chemotherapy can improve oxygen delivery within a tumor by killing cells and reducing oxygen demand, which matters because oxygen-starved tumor regions resist radiation. Drugs can also inhibit the rapid regrowth of tumor cells between radiation sessions and interfere with the blood vessel formation that tumors rely on to sustain themselves.4PubMed. Biological basis for chemo-radiotherapy interactions All of these interactions add up to a treatment that is genuinely more than the sum of its parts.

Why Not Just Give Them One After the Other?

Sequential chemoradiation, where a patient completes a full course of chemotherapy and then starts radiation (or vice versa), was the earlier approach. It has a simpler side-effect profile because the body recovers from one insult before facing the next. But head-to-head trials have consistently shown that simultaneous delivery produces better survival outcomes for locally advanced disease, even though it is harder on patients.

A Cochrane review pooling data from six randomized trials in non-small cell lung cancer found that concurrent delivery reduced the risk of death by about a quarter compared with sequential treatment, translating to roughly a ten percentage-point improvement in two-year survival.5Cochrane Database of Systematic Reviews. Concurrent chemoradiotherapy in non-small cell lung cancer A landmark U.S. trial, RTOG 9410, confirmed that five-year survival was higher with concurrent cisplatin-based chemoradiation than with sequential delivery.6JNCI: Journal of the National Cancer Institute. Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 A separate randomized study using cisplatin and vinorelbine found that median survival jumped from about 13 months with sequential therapy to nearly 17 months with concurrent delivery, and tumor response rates climbed from roughly half to 80 percent.7PubMed. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

The survival benefit comes at a cost. Concurrent treatment produces more severe short-term side effects than sequential schedules, particularly inflammation of the esophagus (esophagitis) in lung cancer patients and severe mouth sores (mucositis) in head and neck cancer patients. This trade-off means that not every patient is a candidate for the concurrent approach, a question explored further below.

Where CCRT Is the Standard Treatment

CCRT has become the backbone of treatment for several cancers that are too advanced to remove surgically but have not spread to distant organs. These “locally advanced” tumors sit in a challenging middle ground: surgery alone will not get clean margins, and radiation alone does not produce adequate long-term control. The cancers where CCRT is most firmly established include:

In rectal cancer, CCRT is frequently used before surgery rather than as the definitive treatment. This “neoadjuvant” approach aims to shrink the tumor enough to make complete surgical removal more feasible and to improve the odds of preserving the anal sphincter. In one trial of preoperative chemoradiation for locally advanced rectal cancer, about half the resected tumors showed downstaging from their initial imaging, and roughly a quarter had a complete pathological response, meaning no residual cancer was found in the surgical specimen.12British Journal of Cancer. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2) A similar downstaging benefit has been observed in perihilar bile duct cancers, where neoadjuvant CCRT shifted tumor staging favorably compared with surgery without prior treatment.13PubMed Central. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma

The Cisplatin Dosing Debate in Head and Neck Cancer

Cisplatin is the most widely used concurrent chemotherapy drug in head and neck CCRT, but how to dose it remains a genuine area of disagreement. The original evidence came from trials using high-dose cisplatin at 100 milligrams per square meter of body surface, given every three weeks for up to three cycles during radiation. That regimen is effective but brutal: severe acute side effects occurred in about 85 percent of patients in one head-to-head trial.14PubMed. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial

Weekly low-dose cisplatin (typically 30-40 milligrams per square meter) has gained popularity as a gentler alternative. Patients tolerate it better, with fewer severe toxicities and a higher likelihood of completing all planned chemotherapy cycles.15PubMed Central. Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas However, the same study found that the three-weekly high-dose schedule produced better local tumor control, a finding echoed by the phase III trial mentioned above, which showed that three-weekly cisplatin resulted in superior local-regional control despite its heavier toxicity burden.14PubMed. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial

A meta-analysis pooling available evidence found no statistically significant difference in overall survival or progression-free survival between weekly and three-weekly cisplatin, and overall treatment compliance was similar.16PubMed. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis What that practically means is that oncologists still have to make a judgment call. For younger, fitter patients with bulky tumors, the three-weekly schedule may offer a local control edge. For older patients or those with kidney problems who might not survive the toxicity of high-dose cisplatin, weekly dosing can deliver a similar overall survival benefit with a lighter side-effect load. This is a situation where missing chemotherapy cycles matters: in one large analysis, each missed weekly cisplatin cycle was associated with roughly double the risk of death.17JAMA Network Open. Weekly Cisplatin Cycles and Outcomes for Chemoradiation in Head and Neck Cancer So whichever schedule is chosen, actually completing it is critical.

What the Side Effects Look Like

Because CCRT delivers two toxic therapies simultaneously, it stresses the body considerably more than either treatment alone. A detailed study of head and neck cancer patients undergoing CCRT found that high-grade mucositis (painful inflammation and ulceration of the mouth and throat lining) was present in virtually every patient. About a quarter of patients needed hospitalization for dehydration or malnutrition, another quarter developed pneumonia, and roughly half had blood-count abnormalities. Nearly half experienced treatment delays related to toxicity.18JAMA Otolaryngology–Head & Neck Surgery. Adverse Events Associated With Concurrent Chemoradiation Therapy in Patients With Head and Neck Cancer

Long-term side effects are a separate concern. A ten-year follow-up of lung cancer patients treated with CCRT found that nearly 60 percent developed late toxicities, the most common being radiation-induced lung scarring (pulmonary fibrosis), which affected about 40 percent. In fact, every patient still alive at the final follow-up had developed fibrosis with some degree of breathing difficulty. Other long-term effects included hearing damage and persistent swallowing problems.19PubMed Central. Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer These late effects are an important part of the conversation between doctors and patients, because surviving the cancer means living with the consequences of treatment.

Who Can Tolerate CCRT

Not every patient with a locally advanced cancer is a good candidate for concurrent chemoradiation. The trials that proved CCRT’s superiority over other approaches enrolled relatively fit patients, and in the general population a substantial proportion of people diagnosed with locally advanced cancer would not have met those trial criteria due to age, other health conditions, or poor physical function.

In practice, oncologists assess patients using performance status scores, which gauge how well someone can carry out daily activities. Patients with poor functional status are significantly less likely to tolerate the full course of treatment. One study of lung cancer patients found that a performance status score of two or higher (meaning the person is up and about more than half of waking hours but cannot do much work) was associated with sharply lower odds of completing therapy. Being underweight (a body mass index below 18.5) independently predicted poor tolerance as well.20PubMed. Associations of Pretreatment Physical Status Parameters with Tolerance of Concurrent Chemoradiation and Survival in Patients with Non-small Cell Lung Cancer For patients who cannot handle concurrent delivery, sequential chemoradiation or radiation alone remain alternatives, trading some efficacy for a more manageable treatment course.

Nutrition and Supportive Care During Treatment

Given how physically demanding CCRT is, the support structure around the treatment matters as much as the treatment itself. Weight loss during CCRT is extremely common and is directly linked to worse outcomes, partly because patients who lose too much weight experience more treatment interruptions. A study comparing proactive nutritional intervention (starting dietary support early, often with a feeding tube placed before treatment begins) to standard care found that patients receiving early nutrition support had roughly half as many radiation breaks due to toxicity. Those in the standard group lost significantly more weight, had more days of delayed radiation, and the correlation between weight loss and treatment delays was essentially linear: the more weight lost, the more days missed.21PubMed. Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy

Beyond nutrition, supportive care during CCRT typically involves anti-nausea medications, pain management, intravenous fluids for dehydration, blood transfusions or growth factors for low blood counts, and close monitoring of kidney and hearing function (both of which cisplatin can damage). The goal is to keep the patient well enough to complete the planned course, because interrupted or shortened treatment compromises the survival benefit that justified the concurrent approach in the first place.

Immunotherapy After CCRT

One of the most significant recent advances in CCRT-treated cancers is the addition of immunotherapy after chemoradiation is complete. The PACIFIC trial, published in 2017, tested the immune checkpoint drug durvalumab as “maintenance” therapy in patients with unresectable stage III non-small cell lung cancer who had finished CCRT without their cancer progressing. The results were striking: median progression-free survival was about 17 months with durvalumab compared with less than 6 months with placebo.22PubMed. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer Follow-up data confirmed a meaningful improvement in overall survival as well.23PubMed Central. The role of chemoradiotherapy and immunotherapy in stage III NSCLC

This combination has rapidly become the new standard of care for unresectable stage III lung cancer. The rationale is partly biological: chemoradiation damages tumor cells in ways that release signals attracting the immune system, and checkpoint immunotherapy then prevents the tumor from shutting that immune response down. Researchers are also investigating whether specific tumor mutations affect how well this strategy works. Early data from patients with KRAS-mutated lung cancers, a common mutation subtype, showed that progression-free survival and overall survival after CCRT plus durvalumab consolidation were comparable to those in patients without actionable mutations, suggesting the benefit is broad rather than limited to certain molecular subtypes.24Clinical Lung Cancer. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer

The Hypoxia Problem

One persistent challenge in making CCRT more effective is tumor hypoxia. Tumors frequently outgrow their blood supply, leaving pockets of cells with very little oxygen. This matters because radiation works partly by generating reactive oxygen molecules that damage DNA, and when oxygen is scarce, that process is less efficient. Hypoxic tumor regions can be two to three times more resistant to radiation than well-oxygenated regions.

Research is ongoing to overcome this barrier. Some strategies involve drugs that improve oxygen delivery to tumors, and functional imaging techniques are being explored to map hypoxia within tumors so radiation doses can be tailored accordingly. In a phase I trial combining bevacizumab (an anti-blood-vessel drug) with CCRT for head and neck cancer, imaging showed significant reductions in both tumor hypoxia and tumor cell proliferation after the combined treatment.25PubMed Central. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion These approaches remain experimental, but they represent a clear path toward making each radiation fraction count for more.

The Financial and Personal Burden

CCRT’s intensity extends beyond the physical. Treatment typically runs five to seven weeks, with daily radiation visits and periodic chemotherapy infusions, and patients often cannot work during that period. The financial strain can be severe. In a study of patients undergoing CCRT, more than half reported experiencing financial hardship at baseline, before treatment had even begun, driven by the cascade of appointments, diagnostic tests, and lost income that precede the first day of therapy.26PubMed Central. Predictors of Financial Toxicity in Patients Receiving Concurrent Radiation Therapy and Chemotherapy About a quarter of patients saw their financial situation worsen further during treatment, and being hospitalized for side effects was independently associated with that worsening.

For cervical cancer patients, who are often younger women, the burden extends to caregivers. A study of patient-caregiver pairs found that high caregiver burden was linked to catastrophic out-of-pocket expenses, particularly for families who had to travel long distances for daily radiation. Patients with the worst financial strain had significantly more unplanned treatment interruptions, which stretched overall treatment times and could compromise effectiveness.27ESMO Open. Financial toxicity and caregiver burden in definitive concurrent chemoradiation for cervical cancer Financial toxicity is increasingly recognized as a genuine barrier to the success of CCRT, not just an unfortunate side effect of having cancer. Oncology teams that identify financial risk early and connect patients with social work, transportation assistance, or flexible scheduling can prevent the kind of treatment breaks that erode the survival benefits the whole approach is built on.

How Radiation Technology Has Evolved Alongside CCRT

The radiation half of CCRT has not stood still. Older techniques delivered broad beams that inevitably exposed large volumes of healthy tissue to significant doses, contributing to side effects like esophagitis in lung cancer treatment and dry mouth in head and neck treatment. Intensity-modulated radiation therapy, or IMRT, uses computer-optimized beam angles and varying intensities to concentrate dose on the tumor while sparing surrounding structures. A major U.S. cooperative group trial found that IMRT significantly reduced the rate of severe radiation-induced lung inflammation compared with older three-dimensional planning techniques, and IMRT has since become the standard delivery method for stage III lung cancer treated with CCRT.28Elsevier / Clinical and Translational Radiation Oncology. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer These improvements in radiation precision do not change the fundamental logic of CCRT, but they expand the pool of patients who can tolerate it by reducing the collateral damage to healthy organs.

Written by

Jalisa Cannon

At a radiation oncology clinic in Naperville, Illinois, Jalisa Cannon, RN, OCN, cares for patients undergoing cancer therapy. A nursing graduate of the University of Louisiana at Lafayette, she worked in outpatient chemotherapy before shifting to radiation treatments. She educates patients on skin care and manages on-treatment side effects, and she writes for Biology Insights.